Literature DB >> 18485044

Patterns of intervention for renal lesions in von Hippel-Lindau disease.

Surena F Matin1, Kamran Ahrar, Christopher G Wood, Molly Daniels, Eric Jonasch.   

Abstract

OBJECTIVE: To review the records of patients at our centre with von Hippel-Lindau (VHL) disease, to determine the incidence of renal cell carcinoma (RCC) and patterns of intervention using minimally invasive therapies. PATIENTS AND METHODS: Patients with genetically confirmed VHL were evaluated in a multidisciplinary clinical care centre established in 2003. Patients were preferentially offered percutaneous radiofrequency ablation (RFA). Cystic tumours were considered contraindications to RFA, as were larger tumours or extensive multifocality with tumours of >3 cm. These patients had either open partial nephrectomy (OPN) or, in unsalvageable cases, radical nephrectomy.
RESULTS: Of 38 patients with VHL, 16 (42%) were found to have RCC; two with small tumours are under observation. Fourteen of the 16 have had a total of 25 renal interventions, none of whom has progressed to end-stage renal disease. OPN was performed in 15 (60%) cases, including those who had had multiple bilateral procedures; RFA was used in five (20%) cases. After median follow-up of 41 months, local recurrence was detected in 33%; the metastasis-free survival rate was 93.3% and overall survival 87.5%.
CONCLUSIONS: Of patients with VHL, 88% with renal involvement require interventions for their kidneys. OPN is the primary method used, and was successful both as a primary and secondary procedure in 60% of cases. In only 20% was RFA possible due to limitations of current technology. The introduction of protocol-based targeted therapies holds the promise of reducing the number of interventions required for treating VHL.

Entities:  

Mesh:

Year:  2008        PMID: 18485044     DOI: 10.1111/j.1464-410X.2008.07718.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

1.  Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up.

Authors:  C A Jilg; Hartmut P H Neumann; S Gläsker; O Schäfer; C Leiber; P U Ardelt; M Schwardt; W Schultze-Seemann
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

2.  Active surveillance of renal masses in von Hippel-Lindau disease: growth rates and clinical outcome over a median follow-up period of 56 months.

Authors:  Jin Zhang; Jia-Hua Pan; Bai-Jun Dong; Wei Xue; Dong-Ming Liu; Yi-Ran Huang
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

Review 3.  Role of VHL gene mutation in human renal cell carcinoma.

Authors:  Wani Arjumand; Sarwat Sultana
Journal:  Tumour Biol       Date:  2011-11-29

4.  Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review.

Authors:  Kyung Hwa Choi; Young Dong Yu; Moon Hyung Kang; Dong Soo Park
Journal:  Can Urol Assoc J       Date:  2015-09-09       Impact factor: 1.862

5.  A comparison of outcomes for standard and multiplex partial nephrectomy in a solitary kidney: The National Cancer Institute experience.

Authors:  Joseph A Baiocco; Mark W Ball; Asha K Pappajohn; Kareem N Rayn; Gennady Bratslavsky; Shawna L Boyle; William M Linehan; Adam R Metwalli
Journal:  Urol Oncol       Date:  2019-03-20       Impact factor: 3.498

6.  Invasive management of renal cell carcinoma in von Hippel-Lindau disease.

Authors:  Diego M Carrion; Estefanía Linares-Espinós; Emilio Ríos González; Alfredo Aguilera Bazán; Mario Alvarez-Maestro; Luis Martinez-Pineiro
Journal:  Cent European J Urol       Date:  2020-05-20

7.  Management for patients with de novo or recurrent tumors in the residual kidney after surgery for nonfamilial bilateral renal cell carcinoma.

Authors:  Noboru Hara; Tsutomu Nishiyama; Norihiko Yoshimura; Satoshi Takaki; Kyoichiro Yamakado; Yasuo Kitamura; Kazuya Suzuki; Kota Takahashi
Journal:  Adv Urol       Date:  2009-11-30

Review 8.  Renal cancer in von Hippel-Lindau disease and related syndromes.

Authors:  Birke Bausch; Cordula Jilg; Sven Gläsker; Alexander Vortmeyer; Niklas Lützen; Alexandra Anton; Charis Eng; Hartmut P H Neumann
Journal:  Nat Rev Nephrol       Date:  2013-07-30       Impact factor: 28.314

9.  Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma.

Authors:  Kenan Ashouri; Sophia Mohseni; John Tourtelot; Pranav Sharma; Philippe E Spiess
Journal:  J Kidney Cancer VHL       Date:  2015-09-25

Review 10.  Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies.

Authors:  Emily Kim; Stefan Zschiedrich
Journal:  Front Pediatr       Date:  2018-02-09       Impact factor: 3.418

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.